Project

Boehringer Ingelheim BI1366-0031_456906_SSc

Ongoing - recruitment active ยท 2023 until 2026

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2023
End Date
2026
Financing
Others
Brief description/objective

A Phase II, randomised, placebo-controlled, double-blind,
parallel-group, efficacy and safety study of at least 48 weeks of
oral BI 685509 treatment in adults with early progressive diffuse
cutaneous systemic sclerosis